Fighting counterfeit medicines in Europe: the effect on access to medicines

The implementation of the Falsified Medicines Directive, and its Delegated Regulation with detailed specifications of safety features, will provide an additional obstacle for counterfeiters. The implementation of the Directive aims to prevent falsified medicines from reaching patients, and is in the interest of public health. However, the financial burden for manufacturers to implement these additional safety features, as well as the repository system that will allow the verification of authenticity of individual packs of medicine, may threaten the availability of medicines.

Authors

Maarten Van Baelen, Pieter Dylst, Catarina Lopes Pereira, Johan Verhaeghe, Koen Nauwelaerts, Susie Lyddon

Read more

2017 Market Review – Biosimilar Medicines Markets – Policy Overview

US FDA Advisory committee hears first-hand about the decade of EU experience with biosimilar medicines use

Medicines for Europe Director General Adrian van de Hoven participated in the Open Public Hearing (OPH) of the July 13, 2017 Oncologic Drugs Advisory Committee US FDA Advisory Committee involving biosimilar medicines on 13 July 2017.

The Benefits of Biosimilar Medicines

Join Medicines for Europe – 2017

Medicines for Europe Country Specific Market Access Policies

Biosimilars in the EU – Information guide for healthcare professionals

The Impact of Biosimilar Competition in Europe

Universal Access to Health, How Can We Contribute?

AGENDA

9.30 Coffee & Registration

10.00 Introduction: the event, rationale of the partnership, 4th edition, goal of the debate, setting

Moderator:  Sarantis Michalopoulos, Euractiv

10.15 Welcome Address and MEPs’ perspectives

  • MEP José Inácio Faria, EPP group, PT
  • MEP Andrey Kovatchev, EPP group, BU

10.30 European Commission’s overview

  • Sylvain Giraud, Head of Unit, DG Santé

10.45 Stakeholders’ perspectives on improving access to healthcare

  • Nicola Bedlington (EPF)
  • Arnaud Emériau (ESIP)
  • Yannis Natsis (EPHA)
  • Adrian van den Hoven (Medicines for Europe)

11:45  Exchange of views

12:15  Questions and answers

12.30  Networking Lunch

REGISTRATION

Tweetup with Jacek Glinka | Friday 24 March 2017 | 10.00 – 10.45 (CET)

15th Biosimilar Medicines Conference

BIOSIMILAR MEDICINES: A GAME CHANGER FOR HEALTHCARE SUSTAINABILITY

Friday 24 March 2017 | 10.00 – 10.45 (CET)

CONNECT BY USING THE HASHTAG
#ASKJACEKGLINKA